

We claim:

1. An antibody or antigen-binding fragment thereof that binds to PAR2 comprising a heavy chain variable domain (VH) and a light chain variable domain (VL),
5 wherein the VH comprises:
i) a VH-CDR1 having the amino acid sequence of SEQ ID NO: 13,
ii) a VH-CDR2 having the amino acid sequence of SEQ ID NO: 14,
iii) a VH-CDR3 having the amino acid sequence of SEQ ID NO: 15,
and wherein the VL comprises:
10 i) a VL-CDR1 having the amino acid sequence of SEQ ID NO: 18,
ii) a VL-CDR2 having the amino acid sequence of SEQ ID NO: 19,
iii) a VL-CDR3 having the amino acid sequence of SEQ ID NO: 20.
2. The antibody or antigen-binding fragment thereof of claim 1, wherein the VH
15 comprises an amino acid sequence that is at least 80%, 85%, 90%, 92%, 93%, 95%, 97%,
99% or 100% identical to SEQ ID NO: 12 and wherein the VL comprises an amino acid
sequence that is at least 80%, 85%, 90%, 92%, 93%, 95%, 97%, 99% or 100% identical to
SEQ ID NO: 17.
- 20 3. The antibody or antigen-binding fragment of claim 1, wherein the VH
comprises an amino acid sequence corresponding to SEQ ID NO: 12 and wherein the VL
comprises an amino acid sequence corresponding to SEQ ID NO: 17.
4. The antibody or antigen-binding fragment of any one of claims 1 to 3, wherein
25 the antigen-binding fragment is an scFv or a Fab'.
5. The antibody or antigen-binding fragment of any one of claims 1 to 4, wherein
the antibody is a monoclonal antibody.
- 30 6. The antibody or antigen-binding fragment of any one of claims 1 to 5, wherein
the antibody or antigen-binding fragment prevents trypsin, tryptase and/or matrilysin from
interacting with PAR2.

7. The antibody or antigen-binding fragment of any one of claims 1 to 6, wherein the antibody or antigen-binding fragment binds to PAR2 with greater affinity at a pH of 7.4 than at a pH of 6.0.
- 5
8. A nucleic acid capable of expressing the antibody or antigen-binding fragment of any one of claims 1 to 7.
9. One or more nucleic acids comprising a nucleotide sequence that is at least 10 90% or 95% or is 100% identical to SEQ ID NO: 11 and encodes a heavy chain variable domain (VH), and a nucleotide sequence that is at least 90% or 95% or is 100% identical to SEQ ID NO: 16 and encodes a light chain variable domain (VL), wherein the VH comprises:
- 15
- i) a VH-CDR1 having the amino acid sequence of SEQ ID NO: 13,
 - ii) a VH-CDR2 having the amino acid sequence of SEQ ID NO: 14,
 - iii) a VH-CDR3 having the amino acid sequence of SEQ ID NO: 15,
- and wherein the VL comprises:
- 20
- i) a VL-CDR1 having the amino acid sequence of SEQ ID NO: 18,
 - ii) a VL-CDR2 having the amino acid sequence of SEQ ID NO: 19,
 - iii) a VL-CDR3 having the amino acid sequence of SEQ ID NO: 20.
10. A vector comprising the one or more nucleic acids of claim 9.
11. A set of vectors comprising: a) the nucleic acid encoding the VH of claim 9; 25 and b) the nucleic acid encoding the VL of claim 9.
12. A host cell comprising one or more of the vectors of claim 10 or claim 11.
13. A composition comprising a pharmaceutically acceptable carrier and the 30 antibody or antigen-binding fragment of any one of claims 1 to 7.
14. A kit comprising the composition of claim 13.

15. A kit comprising the antibody or antigen-binding fragment of any one of claims 1 to 7.

16. Use of the antibody or antigen-binding fragment of any one of claims 1 to 7,
5 or the composition of claim 13 in the manufacture of a medicament for treating pain in a subject in need thereof, wherein a pharmaceutically effective amount of the antibody, the antigen-binding fragment or the composition is to be administered to the subject.

17. Use of the antibody or antigen-binding fragment of any one of claims 1 to 7,
10 or the composition of claim 13 in the manufacture of a medicament for treating pain in a subject in need thereof.

18. The antibody or antigen-binding fragment of any one of claims 1 to 7, or the composition of claim 13 for use in therapy.
15